c-Triadem: A constrained, explainable deep learning model to identify novel biomarkers in Alzheimer's disease.

Alzheimer's disease (AD) is a neurodegenerative disorder that requires early diagnosis for effective management. However, issues with currently available diagnostic biomarkers preclude early diagnosis, necessitating the development of alternative biomarkers and methods, such as blood-based diagnostics. We propose c-Triadem (constrained triple-input Alzheimer's disease model), a novel deep neural network to identify potential blood-based biomarkers for AD and predict mild cognitive impairment (MCI) and AD with high accuracy. The model utilizes genotyping data, gene expression data, and clinical information to predict the disease status of participants, i.e., cognitively normal (CN), MCI, or AD. The nodes of the neural network represent genes and their related pathways, and the edges represent known relationships among the genes and pathways. We trained the model with blood genotyping data, microarray, and clinical features from the Alzheimer's Neuroimaging Disease Initiative (ADNI). We demonstrate that our model's performance is superior to previous models with an AUC of 97% and accuracy of 89%. We then identified the most influential genes and clinical features for prediction using SHapley Additive exPlanations (SHAP). Our SHAP analysis shows that CASP9, LCK, and SDC3 SNPs and PINK1, ATG5, and ubiquitin (UBB, UBC) expression have a higher impact on model performance. Our model has facilitated the identification of potential blood-based genetic markers of DNA damage response and mitophagy in affected regions of the brain. The model can be used for detection and biomarker identification in other related dementias.